TokenPost·
FDA Extends Capricor’s Deramiocel Review, Sets Nov. 22 Action Date
The amendment includes two-year Phase 3 HOPE-3 extension data and an integrated efficacy summary across HOPE-2 and HOPE-3.
More news
- TokenPostMetis Launches Hybrid Rollup on Devnet With ECC Enabled at Launch
- DecryptNvidia-Backed CoreWeave Is Surging: Here’s What It Means for the AI Boom
- TokenPostAlliance Selects 19 Companies for ALL18 From 2,500 Applications
- TokenPostStarkWare Launches Starknet Proofs for Up to 1.1 Billion L2 Gas
- TokenPostHyperliquid Whale Shorts Exceed Longs by About $508 Million
- CryptoSlateBinance hacker’s XRP stockpile rapidly crashes driven by Bitcoin swaps